Highest-materiality recent filing
Viemed Healthcare reports Q1 2026 revenue of $75.4M, raises full-year guidance
Net revenues increased 28% to $75.4 million for Q1 2026, up from $59.1 million in Q1 2025.
Viemed posts record FY2025 revenue $270.3M; net income +33%; guides FY2026 rev $310-320M
Q4 revenue $76.2M (record, +26% YoY); FY revenue $270.3M (record, +21% YoY).
Viemed Q3 revenue record $71.9M, up 24% YoY; guides FY rev $271-273M
Net revenues $71.9M, a company record, up 24% YoY from $58.0M.
Viemed Q2 net revenue $63.1M (record, +14.7% YoY); diluted EPS $0.08 vs $0.04
Net revenues for Q2 2025 hit $63.1M, a record high, up 14.7% from $55.0M in Q2 2024.
Viemed closes acquisition of Lehan's Medical Equipment for $26M base plus $2.2M earnout
Base purchase price $26M (subject to adjustments) plus estimated contingent consideration of ~$2.2M.
Viemed authorizes share repurchase of up to 1.98M shares (~5% of outstanding) through June 2026
Board authorized repurchase of up to 1,976,441 common shares (approx. 5% of outstanding) through June 2026.
Viemed reports Q1 2025 revenue of $59.1M, up 17% YoY; net income rises 64%
Q1 net revenues $59.1M, 17% increase from $50.6M in Q1 2024.
Viemed acquires Lehan's Medical Equipment for $26M base price; diversifies into women's health
Base purchase price $26M, plus ~$2.2M contingent payments; expected close Q3 2025.
Viemed posts record Q4 revenue $60.7M; full year net revenue $224.3M; issues 2025 guidance
Q4 net revenue $60.7M (+20% YoY); full year $224.3M (+23% YoY).
Viemed Healthcare Q3 2024: revenue up 17.4% to $58M, net income up 33%
Net revenues of $58.0M, a company record; up 17.4% YoY and 5.5% sequentially.
Viemed Q2 2024 revenue hits record $55.0M, up 27% YoY; Adjusted EBITDA up 31%
Net revenues $55.0M (record), up 27% YoY and 9% sequential from Q1 2024.
Viemed Q1 2024 revenue $50.6M, up 28% YoY; net income $1.6M
Net revenues $50.6M for Q1 2024, increase of $11.0M or 28% vs Q1 2023.
Viemed acquires majority stake in East Alabama HomeMed; expects ~$4M annual revenue
Transaction closed April 1, 2024; Viemed gains controlling interest and managerial control of HomeMed.
Viemed reports record Q4 revenue $50.7M (+35% YoY); net income up 43%
Q4 2023 revenue $50.7M, up 35% from $37.5M in Q4 2022; full-year revenue $183.0M, up 32%.
On April 14, 2025, Bruce Greenstein notified Viemed Healthcare, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective immediately.
Max materiality 0.75 · Median 0.57 · Most common event earnings